{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:09:16Z","timestamp":1792372156842,"version":"4.4.0"},"reference-count":150,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Myelodysplastic syndromes\/neoplasms (MDS) represent a biologically and clinically diverse group of myeloid malignancies marked by cytopenias, morphological dysplasia, and an inherent risk of progression to acute myeloid leukemia. Over the past two decades, the field has made significant advances in characterizing the molecular landscape of MDS, leading to refined classification systems to reflect the underlying genetic and biological diversity. In 2025, the treatment of MDS is increasingly individualized, guided by integrated clinical, cytogenetic, and molecular risk stratification tools. For lower-risk MDS, the treatment paradigm has evolved beyond erythropoiesis-stimulating agents (ESAs) with the introduction of novel effective agents such as luspatercept and imetelstat, as well as shortened schedules of hypomethylating agents (HMAs). For higher-risk disease, monotherapy with HMAs continue to be the standard of care as combination therapies of HMAs with novel agents have, to date, failed to redefine treatment paradigms. The recognition of precursor states like clonal hematopoiesis of indeterminate potential (CHIP) and the increasing use of molecular monitoring will hopefully enable earlier intervention\/prevention strategies. This review provides a comprehensive overview of the current treatment approach for MDS, highlighting new classifications, prognostic tools, evolving therapeutic options, and ongoing challenges. We discuss evidence-based recommendations, treatment sequencing, and emerging clinical trials, with a focus on translating biological insights into improved outcomes for patients with MDS.<\/jats:p>","DOI":"10.3390\/cancers17152469","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T14:40:02Z","timestamp":1753454402000},"page":"2469","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Advances and Challenges in the Management of Myelodysplastic Syndromes"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9162-0579","authenticated-orcid":false,"given":"Jessica M.","family":"Stempel","sequence":"first","affiliation":[{"name":"Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4651-5125","authenticated-orcid":false,"given":"Tariq","family":"Kewan","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"ref_1","unstructured":"SEER*Explorer: An Interactive Website for SEER Cancer Statistics [Internet] (2025, February 19). Surveillance Research Program, National Cancer Institute. 17 April 2024. [Updated: 5 November 2024], Available online: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjmed.2012.04.014","article-title":"Epidemiology of Myelodysplastic Syndromes","volume":"125","author":"Ma","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kouroukli, O., Symeonidis, A., Foukas, P., Maragkou, M.-K., and Kourea, E.P. (2022). Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes. Cancers, 14.","DOI":"10.3390\/cancers14225656"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Li, X., Zou, C., Xiang, X., Zhao, L., Chen, M., Yang, C., and Wu, Y. (2025). Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects. Biomolecules, 15.","DOI":"10.3390\/biom15060761"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-023-38515-4","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"14","author":"Kewan","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2352-3026(24)00251-5","article-title":"Data-driven, harmonised classification system for myelodysplastic syndromes: A consensus paper from the International Consortium for Myelodysplastic Syndromes","volume":"11","author":"Komrokji","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101128","DOI":"10.1016\/j.blre.2023.101128","article-title":"Classification, risk stratification and response assessment in myelodysplastic syndromes\/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)","volume":"62","author":"Stahl","year":"2023","journal-title":"Blood Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1182\/blood-2023-186578","article-title":"Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes\/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)","volume":"142","author":"Kewan","year":"2023","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41375-023-01820-4","article-title":"Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M","volume":"37","author":"Gurnari","year":"2023","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/bloodadvances.2018019414","article-title":"The use of immunosuppressive therapy in MDS: Clinical outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv."},{"key":"ref_20","unstructured":"National Comprehensive Cancer Network (2025, January 10). NCCN Clinical Practice Guidelines. Myelodysplastic Syndromes (Version 1.2025). Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1446."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1200\/JCO.22.02699","article-title":"Eltrombopag for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)","volume":"41","author":"Oliva","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/bjh.14792","article-title":"Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: Long-term safety and efficacy","volume":"178","author":"Fenaux","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2018-06-855221","article-title":"Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia","volume":"132","author":"Dickinson","year":"2018","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1182\/bloodadvances.2022009000","article-title":"Health-related quality of life and vulnerability among people with myelodysplastic syndromes: A US national study","volume":"7","author":"Abel","year":"2023","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3324\/haematol.2018.212217","article-title":"Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes","volume":"105","author":"Crouch","year":"2020","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/PPO.0000000000000661","article-title":"Supportive Care for Patients with Myelodysplastic Syndromes","volume":"29","author":"Stempel","year":"2023","journal-title":"Cancer J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e994","DOI":"10.1016\/S2352-3026(23)00265-X","article-title":"Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: A survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Gurnari","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2024024756","article-title":"Risk prediction for clonal cytopenia: Multicenter real-world evidence","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"EVIDoa2200310","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion","volume":"355","author":"List","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_34","first-page":"3671","article-title":"Report of an international working group to standardize response criteriafor myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1016\/S2352-3026(24)00142-X","article-title":"Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): A randomised, double-blind, phase 3 trial","volume":"11","author":"Xicoy","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00277-019-03799-4","article-title":"The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: A review of the literature and expert opinion","volume":"99","author":"Park","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.1997.4013211.x","article-title":"Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model","volume":"99","author":"Negrin","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2008-02-139824","article-title":"Inhibition of the TGF-\u03b2 receptor I kinase promotes hematopoiesis in MDS","volume":"112","author":"Zhou","year":"2008","journal-title":"Blood"},{"key":"ref_41","unstructured":"Celgene Coorporation, Bristol-Myers Squibb Company (2025). REBLOZYL\u00ae (Lusparercept-Aamt) for Injection, for Subcutaneous Use, Celgene Coorporation, Bristol-Myers Squibb Company."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): A multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.21.02476","article-title":"Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients with Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study","volume":"40","author":"Platzbecker","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): Interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1182\/blood-2024-198374","article-title":"Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study","volume":"144","author":"Oliva","year":"2024","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1200\/JCO.2025.43.16_suppl.6512","article-title":"Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)\u2013naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial","volume":"43","author":"Zeidan","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1007\/s12325-025-03208-5","article-title":"Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial","volume":"42","author":"Santini","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1182\/blood-2023-178635","article-title":"The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes","volume":"142","author":"Zeidan","year":"2023","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1002\/hem3.38","article-title":"Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: A retrospective US cohort analysis","volume":"8","author":"Mukherjee","year":"2024","journal-title":"HemaSphere"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2024-208432","article-title":"Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial","volume":"144","author":"Hecht","year":"2024","journal-title":"Blood"},{"key":"ref_52","first-page":"PF634","article-title":"Preliminary efficacy and safety analysis of the MAXILUS study of luspatercept initiated at the maximum approved dose in transfusion-dependent lower-risk myelodysplastic syndromes","volume":"9","author":"Santini","year":"2025","journal-title":"HemaSphere"},{"key":"ref_53","unstructured":"(2025). RYTELO\u00ae (Imetelstat) for Injection, for Intravenous Use, Geron Coorporation."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): A multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood-2024-203612","article-title":"Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory\/Ineligible Lower-Risk Myelodysplastic Syndromes","volume":"144","author":"Platzbecker","year":"2024","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41375-018-0089-x","article-title":"Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: A European LeukemiaNet study","volume":"32","author":"Stauder","year":"2018","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e17406","DOI":"10.1097\/MD.0000000000017406","article-title":"The impact of iron chelation therapy on patients with lower\/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"EVIDoa2200034","DOI":"10.1056\/EVIDoa2200034","article-title":"Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS","volume":"1","author":"Sasaki","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2023-180974","article-title":"Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS","volume":"142","author":"Ross","year":"2023","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1182\/blood-2024-208186","article-title":"Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial","volume":"144","author":"Tan","year":"2024","journal-title":"Blood"},{"key":"ref_62","unstructured":"(2025, June 11). RVU120 for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Neoplasms (MDS), ClinicalTrials.gov ID NCT06243458, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06243458?term=NCT06243458&rank=1."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2023-185259","article-title":"A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia","volume":"142","author":"Adema","year":"2023","journal-title":"Blood"},{"key":"ref_64","first-page":"PF629","article-title":"A randomized, multicenter phase II trial of 3-day decitabine, 3-day azacitidine, or 5-day azacitidine in lower-risk myelodysplastic syndrome","volume":"9","author":"Bouligny","year":"2025","journal-title":"HemaSphere"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2024-204791","article-title":"Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA\u2014Results of the Phase 1-2 Part a of the GFM Combola Study","volume":"144","author":"Ades","year":"2024","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/S2152-2650(23)01206-5","article-title":"Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine\/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis","volume":"23","author":"Bachiashvili","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_67","unstructured":"(2025, June 11). A Study of LB-100 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS), ClinicalTrials.gov ID NCT03886662, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03886662?cond=NCT03886662&rank=1."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2024-206096","article-title":"R289, a Dual Irak 1\/4 Inhibitor, in Patients with Relapsed\/Refractory (R\/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study","volume":"144","author":"Madanat","year":"2024","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2024-198326","article-title":"Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study","volume":"144","author":"Abaza","year":"2024","journal-title":"Blood"},{"key":"ref_70","unstructured":"(2025, June 11). Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome, ClinicalTrials.gov ID NCT04245397, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04245397?cond=NCT04245397&rank=1."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood.2024025131","article-title":"Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT","volume":"145","author":"Gurnari","year":"2025","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age with Advanced Myelodysplastic Syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients with Advanced MDS According to Donor Availability (VidazaAllo Study)","volume":"39","author":"Sockel","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/leu.2015.37","article-title":"HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM","volume":"29","author":"Robin","year":"2015","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Bischof, L., Ussmann, J., Platzbecker, U., Jentzsch, M., and Franke, G.N. (2025). Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcome. Leuk. Lymphoma, 1\u201314.","DOI":"10.1080\/10428194.2025.2476652"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.bbmt.2018.02.007","article-title":"Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience","volume":"24","author":"Alzahrani","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"12342","DOI":"10.18632\/oncotarget.12511","article-title":"Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts","volume":"8","author":"Yahng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41409-024-02365-5","article-title":"Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome","volume":"59","author":"Schroeder","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"106645","DOI":"10.1016\/j.leukres.2021.106645","article-title":"Pre-transplant therapy for patients with myelodysplastic syndromes: A systematic review and meta-analysis","volume":"110","author":"Wang","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_82","first-page":"2047","article-title":"Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood-2024-208034","article-title":"Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes\/Neoplasms (MDS): An Analysis from the International Consorti","volume":"144","author":"Rolles","year":"2024","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF Combined with Decitabine Prophylaxis on Relapse of Patients with High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial","volume":"38","author":"Gao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_86","unstructured":"(2025, February 21). Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT (AMADEUS), ClinicalTrials.gov ID NCT04173533, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04173533."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes","volume":"24","author":"Oran","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_88","unstructured":"(2025, June 11). Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation, ClinicalTrials.gov ID NCT06138587, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06138587?cond=NCT06138587&rank=1."},{"key":"ref_89","unstructured":"(2025, June 11). Pre-Emptive Therapy with DEC-C to Improve Outcomes in MDS Patients with Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant, ClinicalTrials.gov ID NCT04742634, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04742634?cond=NCT04742634&rank=1."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","article-title":"Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia","volume":"29","author":"Fathi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"839.e1-839.e6","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_94","unstructured":"(2025, June 11). Panobinostat Maintenance After HSCT fo High-Risk AML and MDS, ClinicalTrials.gov ID NCT04326764, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04326764?cond=NCT04326764&rank=1."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/leu.2017.242","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)","volume":"31","author":"Bug","year":"2017","journal-title":"Leukemia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/cncr.34762","article-title":"Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study","volume":"129","author":"Ma","year":"2023","journal-title":"Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/bjh.19628","article-title":"Azacitidine combined with interferon-\u03b1 for pre-emptive treatment of AML\/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study","volume":"205","author":"Huang","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2024-203903","article-title":"Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes","volume":"144","author":"Sallman","year":"2024","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1182\/bloodadvances.2023010098","article-title":"Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes","volume":"7","author":"Schulz","year":"2023","journal-title":"Blood Adv."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.23.01159","article-title":"Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients with Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation","volume":"42","author":"Tobiasson","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza\u2122) for Injectable Suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"ref_102","unstructured":"(2025, June 16). Abbvie Press Release, June 16, 2025. AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes. Available online: https:\/\/news.abbvie.com\/2025-06-16-AbbVie-Provides-Update-on-VERONA-Trial-for-Newly-Diagnosed-Higher-Risk-Myelodysplastic-Syndromes."},{"key":"ref_103","unstructured":"(2025, June 11). APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS), ClinicalTrials.gov ID NCT03745716, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03745716?term=apr-246&cond=mds&rank=1&tab=results#more-information."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial","volume":"17","author":"Fenaux","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2024-203569","article-title":"Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS\/Myeloproliferative Neoplasms (MPN)","volume":"144","author":"McCloskey","year":"2024","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Girshova","year":"2022","journal-title":"Blood Adv."},{"key":"ref_107","unstructured":"(2025, June 24). Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants with Myelodysplastic Syndrome (MDS) (ENHANCE), ClinicalTrials.gov ID NCT04313881, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04313881."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_109","unstructured":"(2025, June 24). Tamibarotene Plus Azacitidine in Participants with Newly Diagnosed RARA-Positive Higher-Risk Myelodysplastic Syndrome, ClinicalTrials.gov ID NCT04797780, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04797780?tab=results."},{"key":"ref_110","unstructured":"(2025, July 19). Lisaftoclax (APG-2575) Combined with Azacytidine (AZA) in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (GLORA-4), ClinicalTrials.gov ID NCT06641414, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06641414?term=lisaftoclax%20&rank=3."},{"key":"ref_111","unstructured":"(2025, June 24). A Trial of AK117 (Anti-CD47) in Patients with Myelodysplastic Syndrome, ClinicalTrials.gov ID NCT04900350, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04900350."},{"key":"ref_112","unstructured":"(2025, July 19). A Study of BGB-11417 in Participants with Myeloid Malignancies, ClinicalTrials.gov ID NCT04771130, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04771130?cond=mds&term=sonrotoclax%20&rank=1#study-record-dates."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","article-title":"Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome","volume":"8","author":"Dinardo","year":"2024","journal-title":"Blood Adv."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1182\/blood-2024-201317","article-title":"Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups","volume":"144","author":"Sebert","year":"2024","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2217\/fon-2021-0936","article-title":"Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: Why are we not achieving the promise of clinical trials?","volume":"17","author":"Zeidan","year":"2021","journal-title":"Future Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"260-268.e2","DOI":"10.1016\/j.clml.2023.12.008","article-title":"Real-world Effectiveness of Azacitidine in Treatment-Naive Patients with Higher-risk Myelodysplastic Syndromes","volume":"24","author":"Rajakumaraswamy","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.leukres.2015.12.007","article-title":"Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents","volume":"41","author":"Nazha","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: A phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Griffiths","year":"2020","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): A registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"McCloskey","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.V122.21.386.386","article-title":"A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination with Azacitidine (azaC) In Patients with The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium","volume":"122","author":"Silverman","year":"2013","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized Phase II Study of Azacitidine Alone or in Combination with Lenalidomide or with Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study","volume":"41","author":"Sallman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_126","unstructured":"(2025, March 02). Gilead Press Release, July 21, 2023. Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS. Available online: https:\/\/www.gilead.com\/news\/news-details\/2023\/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds."},{"key":"ref_127","unstructured":"Zeidan, A.M., Xiao, Z., Sanz, G., Giagounidis, A., Sekeres, M., Lao, Z., Deeren, D., Gao, S., Riva, M., and Lee, J. (2024, January 13\u201316). Primary results of the phase III STIMULUS-MDS2 study of sabatolimab + azacitidine vs placebo + azacitidine as frontline therapy for patients with higher-risk MDS or CMML-2. Proceedings of the European Hematology Association Congress 2024, Madrid, Spain. Abstract S180."},{"key":"ref_128","first-page":"E32","article-title":"Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes","volume":"99","author":"Brunner","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"Dinardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: Phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1\u20132 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1182\/blood-2024-209513","article-title":"Azacitidine and Venetoclax in High-Risk Myelodysplastic Syndrome: A Real-World Perspective from the Glam Registry with Long-Term Follow-up","volume":"144","author":"Crisp","year":"2024","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2024-211623","article-title":"Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome\u2014A Multicenter Retrospective Analysis","volume":"144","author":"Ball","year":"2024","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.2024025464","article-title":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes","volume":"145","author":"Garcia","year":"2025","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"TPS7054","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7054","article-title":"Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk myelodysplastic syndromes","volume":"39","author":"Zeidan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(23)00367-8","article-title":"Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: A single-centre, phase 1\/2 study","volume":"11","author":"Bataller","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2021-146932","article-title":"Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group","volume":"138","author":"Sebert","year":"2021","journal-title":"Blood"},{"key":"ref_140","unstructured":"Sebert, M., Clappier, E., Cluzeau, T., Bergugnat, H., Beyne-Rauzy, O., Stamatoullas-Bastard, A., Dimicoli-Salazar, S., Larcher, L., Goldwirt, L., and Thepot, S. (2025, May 12). Ivosidenib Monotherapy in IDH1 Mutated Myelodysplastic Syndrome, Final Results of the IDIOME Trial, a GFM Study. EHA Library, S182 2024. Available online: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422286\/marie.sbert.ivosidenib.monotherapy.in.idh1.mutated.myelodysplastic.syndrome.html."},{"key":"ref_141","first-page":"1845.1841","article-title":"Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)","volume":"114","author":"Sebert","year":"2024","journal-title":"Blood"},{"key":"ref_142","unstructured":"Forma Therapeutics, Inc. (2025). REZLIDHIA\u2122 (Olutasidenib) Capsules, for Oral Use, Forma Therapeutics, Inc."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1182\/blood-2023-187404","article-title":"Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes\/Neoplasms (MDS)","volume":"142","author":"Cortes","year":"2023","journal-title":"Blood"},{"key":"ref_144","unstructured":"(2025, May 12). Olutasidenib in Combination with Hypomethylation Therapy for the Treatment of IDH1-Mutated Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Myeloproliferative Neoplasms. ClinicalTrials.ov ID, Available online: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2024-07758&r=1."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: A phase 1 subgroup analysis of the multicentre, AG221-C-001 trial","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","volume":"7","author":"Dinardo","year":"2023","journal-title":"Blood Adv."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_150","unstructured":"(2024, February 02). Aprea Therapeutics, Press Release December 28, 2020. Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS). Available online: https:\/\/ir.aprea.com\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/15\/2469\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:16:19Z","timestamp":1760033779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/15\/2469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":150,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17152469"],"URL":"https:\/\/doi.org\/10.3390\/cancers17152469","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}